Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no substantive changes to the study details are visible.
    Difference
    0.0%
    Check dated 2026-01-14T03:04:57.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Locations section now lists District of Columbia and New Jersey as study sites. The revision label is updated to Revision: v3.3.3.
    Difference
    0.3%
    Check dated 2025-12-23T17:31:22.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Publications section wording now states automatic population from PubMed and the page revision is updated to v3.3.2, replacing the previous wording and revision v3.2.0.
    Difference
    0.1%
    Check dated 2025-11-24T21:24:43.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The top government funding/operating status notice on the study details page has been removed.
    Difference
    0.3%
    Check dated 2025-11-17T19:17:17.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    No significant changes to core content were detected; only minor formatting adjustments observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T13:43:09.000Z thumbnail image
  8. Check
    103 days ago
    Change Detected
    Summary
    Major update adds a government operations notice and NIH Clinical Center status with a v3.2.0 release; removes a specific resource (Small cell lung carcinoma) from the GARD list and drops the v3.1.0 reference.
    Difference
    2%
    Check dated 2025-10-06T04:22:54.000Z thumbnail image

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.